Optimism

Dr. Zeke Unveils Breakthrough Scoliosis Treatment, Transforming Lives in Austin, TX

Retrieved on: 
Wednesday, March 20, 2024

Scoliosis, a condition characterized by an abnormal curvature of the spine, affects millions worldwide, impacting individuals of all ages.

Key Points: 
  • Scoliosis, a condition characterized by an abnormal curvature of the spine, affects millions worldwide, impacting individuals of all ages.
  • "We believe that every patient deserves the chance to live a life free from the constraints of scoliosis," says Dr. Zeke.
  • As a national leader in scoliosis treatment, Dr. Zeke's clinic has garnered widespread acclaim for its transformative results and compassionate approach.
  • For those suffering from scoliosis, Dr. Zeke's clinic offers a beacon of hope in their journey towards a pain-free and active life.

Japanese Investors Believe Increased Global Urbanisation is Set to Fuel Growth in eVTOL Sector

Retrieved on: 
Tuesday, March 19, 2024

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- New Horizon Aircraft Ltd. (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), a leading hybrid electric Vertical TakeOff and Landing (“eVTOL”) aircraft developer, publishes new global research* that indicates the global trend towards urbanisation is believed by Japanese private equity, venture capital and family office investors to be a key driver behind the anticipated growth in the eVTOL. The study from PureProfile, commissioned by the Company, surveyed investors in Japan responsible for more than $423 billion assets under management.

Key Points: 
  • The study from PureProfile, commissioned by the Company, surveyed investors in Japan responsible for more than $423 billion assets under management.
  • The need to address such transportation issues is believed by 65% of Japanese professional investors to be a key driver behind the growth of the eVTOL market.
  • Only 5% of professional investors in Japan believe the debut date for commercial passenger routes will extend beyond 2030.
  • Roughly three out of four (78%) Japanese investors believe public support for eVTOLs will grow over the next three years with 18% anticipating a dramatic increase in public confidence.

Nano Labs Announces Second Half of 2023 Financial Results

Retrieved on: 
Monday, March 18, 2024

Gross loss was RMB40.6 million (US$5.7 million) for the second half of 2023, compared to a gross profit of RMB53.8 million in the same period of 2022.

Key Points: 
  • Gross loss was RMB40.6 million (US$5.7 million) for the second half of 2023, compared to a gross profit of RMB53.8 million in the same period of 2022.
  • Net loss was RMB120.0 million (US$16.9 million) for the second half of 2023, compared to a net loss of RMB80.3 million in the same period of 2022.
  • Cost of revenues was RMB66.6 million (US$9.4 million) for the second half of 2023, compared to RMB549.2 million for the same period of 2022.
  • Net loss was RMB120.0 million (US$16.9 million) for the second half of 2023, compared with RMB80.3 million in the same period of 2022.

Lincoln Educational Services Corporation Announces Barry Morrow’s Retirement as Chair of the Board and Names John Bartholdson as Chair following the 2024 Annual Meeting of Shareholders

Retrieved on: 
Friday, March 15, 2024

PARSIPPANY, N.J., March 15, 2024 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corporation (Nasdaq: LINC) today announced that J. Barry Morrow has notified the Company’s Board of Directors of his decision not to stand for re-election at the Company’s 2024 Annual Meeting of Shareholders.

Key Points: 
  • PARSIPPANY, N.J., March 15, 2024 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corporation (Nasdaq: LINC) today announced that J. Barry Morrow has notified the Company’s Board of Directors of his decision not to stand for re-election at the Company’s 2024 Annual Meeting of Shareholders.
  • Mr. Morrow joined the Board in 2006 and currently serves as non-executive Chair of the Board.
  • The Company also announced that the Board of Directors had selected current Board member John A. Bartholdson to succeed Mr. Morrow as the next Chair of the Board following the 2024 Annual Meeting of Shareholders to be held in May.
  • Mr. Bartholdson has been a member of the Board of Directors since 2019.

Graphjet Technology, The World’s Only Direct Biomass-to-Graphite Producer, Completes Transaction and Will Begin Trading on Nasdaq

Retrieved on: 
Thursday, March 14, 2024

KUALA LUMPUR, Malaysia, March 14, 2024 (GLOBE NEWSWIRE) -- Graphjet Technology (“Graphjet” or “the Company”), a leading developer of patented technologies to produce graphite and graphene directly from agricultural waste, and Energem Corp. (“Energem”) (Nasdaq: ENCP, ENCPW) today announced they have closed their previously announced business combination (“the Business Combination”). The transaction, which was approved on February 28, 2024, by Energem stockholders, creates the only pure-play publicly traded direct biomass-to-graphite company, establishing the Company as the leading source of graphite and graphene for the U.S market.

Key Points: 
  • Beginning tomorrow, March 15, 2024, Graphjet’s ordinary shares will start trading on Nasdaq under the ticker symbol “GTI.” Graphjet’s warrants will be delisted from Nasdaq and begin trading on the OTC market under the symbol “GTIWW” on March 15, 2024.
  • Graphjet’s CEO, Lee Ping Wei (Aiden Lee), and the rest of the Company’s current management team are expected to remain in leadership positions.
  • “We are thrilled to list Graphjet on the Nasdaq, particularly at this crucial moment of critical material demand and limited availability for the U.S. market,” said Mr. Lee.
  • “On the heels of China’s decision to restrict exports on graphite, we continue to engage in advanced conversations with customers.

Hard market softening for construction sector, but inflation pressures still loom over insurance industry

Retrieved on: 
Thursday, March 14, 2024

However inflation and interest rate uncertainty is still impacting the insurance industry as a whole, after another record year of catastrophic events in 2023.

Key Points: 
  • However inflation and interest rate uncertainty is still impacting the insurance industry as a whole, after another record year of catastrophic events in 2023.
  • That’s according to the Q1 Construction Rate Tracker from WTW, a leading global advisory, broking and solutions company.
  • Yet, construction activity is expected to retract in some countries within Europe and Australia, due to the increased construction costs for projects as a result of economic factors including high inflation, elevated interest rates and labour shortages.
  • Yet, expectations of flat rates and slight discounts for “best in class” risks and clients are indicated in some key territories.

Healthcare Leaders Are Optimistic About 2024 Financial Performance, but Rising Costs Remain a Concern, According to Strata Report

Retrieved on: 
Wednesday, March 13, 2024

CHICAGO, March 13, 2024 (GLOBE NEWSWIRE) -- Despite ongoing expense pressures, leaders at hospitals, health systems, and other healthcare organizations nationwide are optimistic their organizations will build financial health throughout 2024, according to a new report from Strata Decision Technology .

Key Points: 
  • CHICAGO, March 13, 2024 (GLOBE NEWSWIRE) -- Despite ongoing expense pressures, leaders at hospitals, health systems, and other healthcare organizations nationwide are optimistic their organizations will build financial health throughout 2024, according to a new report from Strata Decision Technology .
  • Only 1% of respondents said they were not optimistic about their organization’s financial performance.
  • “For the first time since the pandemic, healthcare leaders have cause to be optimistic about their organizations’ futures,” said Steve Wasson, chief data and intelligence officer with Strata Decision Technology.
  • For 2024, reining in costs — including high labor and non-labor costs — is a top priority for 55% of healthcare leaders.

Osaka Protocol, The spiritual successor to Shiba Inu to launch Decentralized NFT project

Retrieved on: 
Wednesday, March 13, 2024

Such was the case with Shiba Inu where it was a running story where everybody held it and sold it too early and missed out on Life changing wealth.

Key Points: 
  • Such was the case with Shiba Inu where it was a running story where everybody held it and sold it too early and missed out on Life changing wealth.
  • In that case, the founder Ryoshi, famously owned no shiba and encouraged people to take responsibility as if they were the founder themselves.
  • The results speak for themselves with Shiba Inu being a multi-billion dollar coin.
  • Fast forward a few years and we have a similar story brewing, with Osaka Protocol and its (also) mysterious founder named Mephisto.

BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING

Retrieved on: 
Tuesday, March 12, 2024

The proposed expansion will add 7 million square feet of manufacturing and production capabilities.

Key Points: 
  • The proposed expansion will add 7 million square feet of manufacturing and production capabilities.
  • The Dalsem Agreement provides that Dalsem will construct the additional facility to its specifications and build them in a modular fashion.
  • Additionally, the Company has entered into a credit agreement with a lender for a $60 million senior debt financing to fund the expansion construction project (the “Credit Agreement”).
  • This expansion is a direct result of Bright Green obtaining the regulatory approvals for the production of Schedule I and II controlled substances from the DEA and the State of New Mexico Board of Pharmacy.

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

Retrieved on: 
Tuesday, March 12, 2024

Our merger with Newcourt and subsequent listing on Nasdaq confers numerous benefits to our company.

Key Points: 
  • Our merger with Newcourt and subsequent listing on Nasdaq confers numerous benefits to our company.
  • While other companies are exploring synthetic psilocybin, Psyence is the world’s first Nasdaq traded biopharmaceutical company researching a nature-derived (non-synthetic) psilocybin candidate.
  • Furthermore, Psyence is the only publicly traded company to research a non-synthetic psilocybin candidate to treat Adjustment Disorder in the context of Palliative Care.
  • To reflect this exciting new chapter in our company’s evolution, we have created a new investor presentation, which can be found here .